What is P21 | 10MG

P21 | 10MG is a synthetic derivative of Cerebrolysin (specifically CNTF) studied in research for its profound neurogenic, neuroprotective, and cognitive-enhancing properties. It is intended exclusively for research use.

Regarding its chemical identity, P21 has a molecular formula of C24H35N5O5 and a molecular weight of 473.6 g/mol. Its reported canonical sequence is Ac-Pro-Gly-Pro-Ile-Glu. A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include P21.

Product for research use.

Mechanism of action of P21

P21 mimics the action of Ciliary Neurotrophic Factor (CNTF) by binding to the CNTF receptor on brain cells. It specifically inhibits the action of Leukemia Inhibitory Factor (LIF), thereby neutralizing the neuro-inhibitory signals in the brain and promoting massive neurogenesis (the growth of new neurons) and synaptic plasticity.

Pharmacokinetics and pharmacodynamics of P21

P21 is a highly stable, small peptide that crosses the blood-brain barrier exceptionally well. It exerts sustained effects on neurogenesis that outlast its presence in plasma, leading to long-term structural changes in the hippocampus.

Scientific evidence on P21

The available evidence on P21 is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Investigated heavily in models of Alzheimer’s disease, traumatic brain injury, and severe cognitive deficit. Preclinical data indicates it is significantly more effective than native Cerebrolysin at inducing neurogenesis and restoring memory in maze tasks without inducing antibody formation.

P21 applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

P21 protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for P21, so no trial schemes or quantities are specified.

The presentations of this product (10MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of P21

As a general guideline for laboratory handling, lyophilized peptides such as P21 are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 10MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

P21 Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented P21 security profile

The documented safety information in open sources for P21 is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Considered to have a very favorable theoretical safety profile in animal models, lacking the autoimmune risks associated with animal-derived brain extracts. Overstimulation of neurogenesis could theoretically cause headaches or brain fog, but adverse events are rarely documented.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

P21 in a comparative context

P21 is essentially a highly purified, concentrated synthetic fragment of the active components in Cerebrolysin. Compared to Semax (which boosts BDNF), P21 focuses on the CNTF pathway, making it arguably the most potent pure neurogenic peptide currently researched.

History and development of P21

Developed by researchers seeking to isolate the exact active epitope of Cerebrolysin responsible for neurogenesis, aiming to eliminate the risks of injecting large, animal-derived proteins while vastly increasing the potency and stability of the treatment.